PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

Published: August 2016
No. of Pages: 411
Price: Single User: US $ 10995  US $ 8796 Corporate User: US $ 32985  US $ 32985
Single User License: US $ 8796
Corporate User License: US $ 32985

This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 /

Various therapeutic options are available to treat patients with atrial fibrillation (AF), and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially, an antiarrhythmic drug for rhythm control. All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred. The NOACs offer a significant advancement in anticoagulation and their continued uptake will be the main driver of growth in the AF market over the next 10 years.

It is estimated that 2015 sales for AF at approximately $8.0 Billion across the 8MM. The US dominates the overall size of the AF market, generating an estimated $5.7 Billion in 2015 and accounting for 70.6% of the overall size of the market. This is mainly due to the large prevalent AF population in the US, early adoption of the new oral anticoagulants (NOACs), and higher prices for AF medications in this market.

As per Jesus Cuaron, Analyst: “Since the launch of the first NOACs in 2010, this drug class has experienced substantial uptake, accounting for $6.8 billion, approximately 85% of all atrial fibrillation sales revenue across the 8MM in 2015. This uptake will continue to increase, and will be the main driver of growth in the atrial fibrillation space through 2022.

Major drivers for the growth of the AF market over the forecast period will include:

• The continued uptake of the NOACs for the prevention of stroke in patients with AF. Due to the advances that the NOACs provide in terms of improved safety and the lack of a need for routine monitoring, NOAC uptake will continue to increase, taking market share away from the vitamin K antagonists, such as warfarin.

• A shift in AF treatment guidelines to using the CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower-risk patients to receive anticoagulant treatment.

• The approval and launch of the first reversal agents for the NOACs, which will alleviate physician and patient concerns regarding a lack of a reversal agent in the event of uncontrolled bleeding, thereby increasing overall uptake.

Companies attempting to penetrate the AF market and differentiate their products, particularly those companies that market NOACs, are doing so with two main strategies: label expansion to increase physician brand familiarity, and intensive marketing to disseminate clinical trial results. Gaining approval for additional cardiovascular indications has been a strategy that has worked very well for Bayer and Janssen, the two companies that jointly developed and market Xarelto

The report “PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025” provides overview of AF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Specially, this report provides the following analysis:

• Annualized AF therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2015, forecast for ten years to 2025.

• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the AF therapeutics market.

• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

• Analysis of the current and future market competition in the global AF therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: ARCA Biopharma, Armetheon Inc., Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardiome Pharma, Daiichi-Sankyo, Janssen Pharmaceuticals, Isis Pharmaceuticals, Laboratoires Pierre Fabre, Otsuka Pharmaceutical, Pfizer, Portola Pharmaceuticals, Sanofi, Servier, Xention

Published By: GlobalData
Product Code: GlobalData36094

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy